Abstract
This paper engages in a comparative institutional analysis of the private and public risk management programs of the drug isotretinoin, which are designed to prevent the undesired effects isotretinoin has on fetal development. This case study sheds light on the comparative effectiveness of private and public regulation in the pharmaceutical and health care markets. A range of evidence indicates that the private risk management program was more successful in reducing fetal exposures and educating patients about the harmful effects isotretinoin can have on a fetus than the FDA risk management programs designed to accomplish the same goals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
